COVID - search results

Immunity from COVID-19 appears to increase over time between vaccination and infection, and vice versa, according to a new study from OHSU.

A recent study has linked spike protein in the bloodstream with rare cases of myocarditis following vaccination with an mRNA COVID-19 vaccine.

It seems like a slam dunk. Why not repurpose already approved or well-studied drug candidates for conditions where treatments are desperately needed? Wouldn’t that...

Over time people will inevitably get tired of needing two or three booster shots a year. Vaccine uptake will dwindle and we will be back to square one. We are already seeing this happen, with only around 10% of the US population having opted to get the latest bivalent booster.

Research from Rutgers University shows that acute infection with COVID-19 leads to disruptions in the gut microbiome, which may at least partly explain gastrointestinal issues experienced by many patients during the acute and recovery phases of infection.

The cytokine IL-26 may be a biomarker of acute COVID-19 according to a preliminary study by researchers at Karolinska Institute. It may also be a good new target for drug discovery.

Nasopharyngeal cancer drugs worked better in patients who received the SinoVac vaccine than in unvaccinated patients.

COVID-19 activates the same inflammatory response in the brain as Parkinson’s disease and other neurodegenerative conditions, according to research led by University of Queensland (UQ), Australia.

In this session of The State of Biotech, Larry Worden, principal and founder of IVD Logix, discusses how COVID put a spotlight on clinical lab testing and the IVD industry, how this focus impacted non-COVID testing, the trend toward at-home diagnostic testing, the rapid emergence and expansion of new companies and manufacturing capacity for diagnostic testing platforms, and the anticipated reemergence of traditional market dynamics.

A new study has produced a proof of principle for a new “universal” means of treating COVID-19.  Using messenger RNA packaged in lipid nanoparticles, scientists showed in a mouse model that host cells can produce a “decoy” enzyme that binds to coronavirus spike proteins,